FIELD: biotechnology.
SUBSTANCE: disclosed is a method of providing anti-CD19 activity against CD19 expressing cells in a subject. Method comprises administering to a subject a therapeutically effective amount of genetically modified hematopoietic stem cells/precursor cells (HSPC) CD34+ and/or a therapeutically effective amount of genetically modified natural killer cells differentiated from Notch HSPC CD34+ multiplied with agonist. Genetic modification leads to expression of molecules containing extracellular component containing CD19-ligand-binding domain, associated with intracellular component through transmembrane domain. Invention also relates to a kit and composition for providing anti-CD19 activity against CD19 expressing cells containing a therapeutically effective amount of said genetically modified cells.
EFFECT: invention enables the introduction of modified cells to patients for targeting cancer cells without the need to check the immunological compatibility before administration.
49 cl, 37 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| CELL | 2015 |
|
RU2768019C2 |
| TRANSGENIC GENETIC LABELS AND METHODS OF USE | 2015 |
|
RU2822461C1 |
| TRANSGENIC GENETIC LABELS AND METHODS OF USING | 2015 |
|
RU2729112C2 |
| EXPRESSION OF NITROGENASE POLYPEPTIDES IN PLANT CELLS | 2018 |
|
RU2809244C2 |
| IMMUNOTHERAPY CELLS DESIGNED FOR TARGETING ANTIGEN PRESENT SIMULTANEOUSLY ON IMMUNE CELLS AND ON PATHOLOGICAL CELLS | 2015 |
|
RU2714258C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
